We advised Laekna on the placement of new shares

Davis Polk advised Laekna, Inc. on its placement of 17,636,000 new shares, for an aggregate consideration of approximately HK$236 million.

Davis Polk previously advised Laekna, Inc. on its HK$791 million IPO in June 2023. The shares are listed on the Hong Kong Stock Exchange.

Founded in 2016, Laekna, Inc. is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to patients with cancer, metabolic diseases and liver fibrosis around the world. The company has initiated seven clinical trials for LAE102, LAE002 (afuresertib), LAE001 and LAE005 to address unmet medical need in obesity and cancers.

The Davis Polk team included partners Xuelin (Steve) Wang and Jason Xu, counsel Vanessa Chan and associates Jenny Ho and Michelle Chow. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.

Copy link to share post